Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis

PURPOSE: Cancers deficient in homologous recombination DNA repair, such as those with BRCA1 or BRCA2 (BRCA1/2) mutations rely on a pathway mediated by the enzyme poly(adenosine diphosphate-ribose) polymerase (PARP). PARP inhibitors (PARPi’s) have demonstrated efficacy in treating patients with germl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Joyce M., Canzoniero, Jenna, Lee, Seoho, Soni, Sudeep, Mangini, Neha, Santa-Maria, Cesar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065997/
https://www.ncbi.nlm.nih.gov/pubmed/37002487
http://dx.doi.org/10.1007/s10549-023-06910-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065997/
https://www.ncbi.nlm.nih.gov/pubmed/37002487
http://dx.doi.org/10.1007/s10549-023-06910-6

Ejemplares similares